Effect of nutritional screening in children with acute lymphoblastic leukemia undergoing the maintenance chemotherapy.

Background: To investigate the effectiveness of the routine nutritional screening for malnutrition risk in hospitalized children with acute lymphoblastic leukemia (ALL) on maintenance chemotherapy from the viewpoint of clinical outcomes.

Methods: The reviews of 1038 pediatric patients were retrieved for the retrospective, propensity score-matched, superiority study. A 1:1 propensity score matching was utilized to match patients who received nutritional screening (screening cohort) to those who remained usual care without screening (control cohort). The primary endpoint was the long-term event-free-survival (EFS) after the last cycle of maintenance. Secondary outcomes included immune function, complications and long-term quality-adjusted life years (QALYs).

Results: The proportion of cases with risk of malnutrition in screening was 25.8%. At the end of 4 weeks following the last cycle, the level of serum albumin was higher in screening cohort than control cohort (p < 0.001), while the cellular immune function significantly improved in screening cohort (all p < 0.05). During a mean of 11.09 ± 6.45 months follow-up, 28.6% of patients in screening cohort had an event including ALL-related emergency visits, readmitted hospitalizations and severe infections compared to 46.5% of cases in control cohort yielding a hazard ratio of 0.397 (95%CI: 0.306, 0.493 and a significant difference in long-term EFS (24.07 (95%CI: 23.09, 25.04) vs. 18.02 (95%CI: 16.62, 19.42), log-rank p < 0.001). The means of QALYs calculated by area under the curve up to 3, 6, 12 and 24 months after discharge were significantly lower in screening cohort as opposed to control cohort (all p < 0.05).

Conclusions: Pediatric ALL receiving the specific-for-children nutritional screening during hospitalization exhibited a better EFS over the 24-month follow-up than cases without screening. The benefit accounted for a significant improvement in immune function and QALYs scores over long-term follow-up.

Clinical trial number: Not applicable.